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8 April 2020 
 
Another drug bites the dust: A review on the mechanisms of antimalarial drug 
resistance and current preventative intervention 
 
Abstract 
Malaria is a disease transmitted to humans through female mosquito bites. The disease 
is caused by a parasite that advances through a complex life cycle composed of unique 
stages depending on its changing host environments. Millions of people, primarily 
inhabitants of Africa and southeast Asia, succumb to the disease every year. In the past 
few decades, there has been a rise in resistance to current antimalarial therapies, 
sounding the alarm for intervention. Chloroquine, sulfadoxine-pyrimethamine, and 
artemisinin-based combination therapies are among the most potent pharmacological 
tools against the parasite, but mutations in P. falciparum have begun to disarm these 
drugs. This review summarizes mechanisms of action for various antimalarial drugs and 




Malaria has taken victims for thousands of years. The disease was likely reported as far 
back as 2700 BC in febrile individuals living in marshy areas (2). Later, ancient Romans 
noted this observation and coined the disease mal'aria meaning “bad air” (3). Modern 
understanding of malaria began in the 19th century when a French army doctor, 
Charles Louis Alphonse Laveran, analyzed the blood of an ill soldier and found 
crescent-shaped, transparent structures containing a small area of pigment (3). Future 
research would identify the pigment as hemozoin, a byproduct of hemoglobin digestion 
by the malaria-causing parasite. Laveran analyzed blood specimens in several malaria 
patients and ultimately identified the single-celled Plasmodium parasite that caused 
malaria (3).  
 
Surgeon-Major Dr. Ronald Ross spent several years studying various mosquitoes, all of 
which were incapable of hosting malaria. It wasn’t until his discovery on August 20th, 
1987, when he examined an Anopheles mosquito that had fed on a patient infected with 
malaria, eventually giving rise to World Mosquito Day.  He noticed a circular structure in 
its stomach wall. After dissection, it was confirmed that the circular body contained 
malarial pigment. Ross, confident that he had found malaria parasites growing inside of 
the mosquito, designed subsequent experiments using the parasite known to cause 
malaria in sparrows and crows, Plasmodium relictum. He found that the salivary glands 
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of mosquitoes that had fed on malaria-infected birds contained sporozoites, the infective 
form of the malaria-causing parasite. Ross was later awarded the Nobel Prize for his 
discovery of the mosquito stages of malaria (3). 
 
It was known that plasmodium infected red blood cells (RBC), but little information was 
known about the breeding grounds for plasmodium in the human host. Researchers 
aimed to isolate specific organs or organ systems that provided such an environment. 
Studies conducted on rhesus monkeys by collaborators at the Ross Institute of the 
London School of Hygiene and Tropical Medicine found that the primate-specific 
malaria was localized to the liver. Interestingly, livers of human volunteers who were 
knowingly infected with Plasmodium falciparum, displayed similar parasite staging, thus 
the eventual discovery of parasite replication in human tissue (3). 
 
The parasite responsible for malaria in humans can be of several species. The most 
prevalent species are Plasmodium Ovale, Plasmodium Vivax, and Plasmodium 
Falciparum. As Plasmodium Falciparum (P. falciparum) is the most common and 
severe, this review will primarily focus on drug resistance mechanisms in this species. 
 
Malaria Parasite Life Cycle 
Malaria is transmitted from human to human through a mosquito vector. The life cycle of 
the malaria parasite can be broken down into 3 stages; liver stage, blood stage, and 
mosquito stages. The liver and blood stage occur in the human host, and the mosquito 
stage involves maturation in the gut of the mosquito. An infected female mosquito takes 
a blood meal and simultaneously introduces sporozoites into the host bloodstream. The 
sporozoites travel through the blood and eventually invade liver hepatocytes where they 
differentiate into schizonts. Each schizont asexually replicates and after about 7-14 
days, the schizont ruptures releasing thousands of merozoites back into the 
bloodstream, initiating the blood stage (5). Merozoites then hijack host erythrocytes 
where they progress from ring stage to trophozoite to schizont. Mature schizonts 
release new merozoites into the blood after the erythrocytes lyse. These new 
merozoites are able to infect new RBCs and continue the cycle. By signals not clearly 
identified, some ring stage parasites do not become new merozoites but rather they 
differentiate into gametocytes. Gametocytes only enter human blood circulation after 
they have matured. Immature gametocytes are sequestered in the bone marrow, where 
they develop for 6-8 days before release into the bloodstream (16). When subsequent 
mosquitos take a blood meal from an infected host, it is the mature gametocyte that 
gets taken up and undergoes sexual reproduction inside the mosquito. Further 
development occurs in the gut wall and the gametocyte eventually takes refuge in the 
salivary glands of the mosquito(5). Upon the next bite, sporozoites are again injected 
into a human and the cycle repeats. The identification of the malaria parasite life cycle 
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has given researchers specific areas to target when searching for a solution to stop 
malaria transmission.  
 
 
Figure 1. P. falciparum Life Cycle 
The inoculation bite (left) is when the parasite is first introduced into the human 
bloodstream by the mosquito. From here, the parasite continues through the liver stage 
and then blood stage. Upon a second blood meal (right), a different mosquito bites the 
infected host and now harbors the parasite where it will develop inside the mosquito and 
infect another victim at its next blood meal. 
 
 
Plasmodium Falciparum Mechanism of Host Cell Infiltration 
Upon intraerythrocytic infection, P. falciparum must acquire nutrients to satisfy its 
cellular growth demands and cell survival. Initially, the parasite breaks down host RBCs 
and liberates hemoglobin (Hb). The hemoglobin is taken up into the parasite using its 
lysosome-like organelle, called the digestive vacuole. This digestive vacuole is 
distinctive because it does not contain the typical glycosidases or phosphatases seen in 
most digestive vacuoles, suggesting its sole function is hemoglobin degradation (9,17). 
Further degradation of the hemoglobin produces small peptides and eventual amino 
acids for use in parasite protein synthesis. However, hemoglobin is not an excellent 
source of amino acids, suggesting that the parasite digests hemoglobin for other 
benefits as well (15). This was demonstrated in a study where the parasite was placed 
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in culture surrounded by 20 essential amino acids and the parasite still degraded 
hemoglobin (17). During Hb digestion, irreversible, rapid oxidation of Fe2+ to Fe3+ 
forms a toxic byproduct, free ferriprotoporphyrin IX (FPIX) heme (5). FPIX heme, if left 
untouched, is injurious to the parasite cell membrane as malarial parasites lack the tools 
for processing FPIX via heme oxygenase pathway. To avert damage and promote stage 
growth, the parasite converts FPIX heme to nontoxic, crystalline hemozoin (Hz) (5). 
Hemozoin is the substance visible in cells, commonly known as malaria pigment.  
 
Chloroquine Use in the Treatment of Malaria and Related Resistance Mechanism 
Initial malaria treatment began with the use of chloroquine in 1946, after widespread 
clinical trials found no substantial toxic side effects. Its relatively low production and 
distribution costs combined with high clinical efficacy made it one of the best weapons 
against malaria (6). Since its inception, widespread use of chloroquine applied a forceful 
selection pressure to P. falciparum and the parasite was forced to adapt. About 13 
years later, in 1959, the first reported cases of chloroquine resistance emerged from 
South America and again from southeast Asia one year later (6,1) From these foci, the 
chloroquine-resistant parasite rapidly spread to other continents in all directions. Its 
arrival in Africa is of special concern because this region faces financial and clinical 
compliance blocks that leave chloroquine as the only affordable and practical 
pharmacological treatment method accessible for infected individuals. 
 
Antimalarial activity of chloroquine is made difficult by the changes in parasite life cycle, 
specifically when looking at intraerythrocytic vs exoerythrocytic stages. Each stage 
exists in a unique chemical environment and is surrounded by specialized enzymes and 
degradation processes. Chloroquine (CQ), a weak base, acts on the parasite in the 
intraerythrocytic stage. Once administered, CQ freely diffuses across the membrane of 
the parasite digestive vacuole. Here, the chloroquine binds up the free 
ferriprotoporphyrin IX (FPIX) heme, preventing its conversion to Hz (5). Additionally, the 
acidic vacuolar pH of about 5- 5.4 protonates CQ, preventing diffusion out of the 
vacuole (9, 17). The chloroquine-FPIX heme complex accumulates within the vacuole 
and eventually poisons the parasite with its own toxic metabolic byproducts. 
 
P. falciparum chloroquine-resistance transporter (PfCRT) and PfMDR as a co-
modulator 
Unfortunately, resistance to CQ emerged not long after its widespread use. Analysis of 
antimalarial-resistant parasites showed decreased concentrations of chloroquine in the 
digestive vacuole. Several allelic studies and genetic crosses identified an association 
with polymorphisms in the pfcrt gene with lower levels of chloroquine accumulation in 
the vacuole. The pfcrt gene codes for a 10-transmembrane helices PfCRT protein 
consisting of 424 amino acids that inserts in the membrane of the digestive vacuole and 
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assists in transport across the membrane. It is known that the PfCRT variants contain 
anywhere from 4-10 non-synonymous mutations, making this protein extremely complex 
(11, 13). Although many polymorphisms have been identified, replacement of K76 by 
76T seems to be one mutation that is routinely present in chloroquine-resistant 
parasites (1). It is suggested that the loss of the positive lysine residue accounts for the 
acquisition of the ability of mutant PfCRT to export protonated chloroquine from the 
vacuole. Junge et al. conducted a proteoliposome study in which it was discovered that 
CQ-resistant P. falciparum showed higher CQ export activity, but CQ-sensitive 
accumulated higher concentrations of CQ. This concluded that CQ-resistant variants 
bypass toxic effects of CQ by increased transport activity out of the digestive vacuole 
(11). Subsequent research demonstrated that although chloroquine transport was lost 
when removing K76T mutation, wild type pfcrt introduced to K76T mutation was not 
enough to permit chloroquine export from the cell (9). Other factors such as dosing, pre-
existing immunity, and whether or not the infection was caused by chloroquine-tolerant 
or chloroquine-resistant parasites also play a role in treatment success. A study found 
that individuals without the Thr76 mutations were highly likely to find success in 
chloroquine treatment, while individuals with the mutation indicated a 33% treatment 
failure rate (7). Current literature identifies mutant PfCRT as a marker for chloroquine 
treatment failure, but recognizes there must be additional players modulating 
resistance.  
 
The P. falciparum multidrug resistance gene (pfmdr) has been heavily studied as a co-
modulator for chloroquine-resistance. This gene codes for a p-glycoprotein homolog 
that is a transmembrane protein in mammals, which is also involved in membrane 
transport. Studies suggest that the N86Y mutation encourages chloroquine-resistance 
but several others such as Y184F, S1034C, and D1246Y also exist and influence 
derivatives similar to CQ (1). Increases in gene copy numbers are associated with 
decreased clinical efficacy after treatment with other antimalarial drugs as well. 
Mutations in the pfmdr gene have also been associated with cancer resistant drugs in 





Figure 2. Digestive Vacuole Membrane 
(Left) PfCRT transmembrane protein embedded in the digestive vacuole membrane of 
P. falciparum facilitating entry of chloroquine (CQ) into the vacuole. (Right) Mutated 




P. falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-tr) and P. 
falciparum dihydropteroate synthetase (PfDHPS) as Second Line Defense 
Resistance to CQ treatment soon emerged and the second line of defense was 
developed: a coformulation therapy, sulfadoxine-pyrimethamine (SP). The two drugs act 
synergistically on the folate synthesis pathway in the parasite (1). An important gene, 
pfdhps, codes for the PfDHPS enzyme that catalyzes the parasitic reaction synthesizing 
dihydrofolate, a precursor required to make pyrimidines (11). Pyrimidines are a class of 
bases used to synthesize RNA and DNA. PfDHPS has 5 known mutations (S436A/F, 
A437G, L540E, A581G, and A613T/S) and inhibits the action of the sulfa drugs, 
rendering sulfa drugs useless in the SP coformulation therapy (11). Sulfa drugs 
normally inhibit folate synthesis. 
 
A co-modulating gene in SP resistance is pfdhfr-ts, which codes for the PfDHFR 
enzyme. The two primary responsibilities of this enzyme are to reduce dihydrofolate into 
tetrahydrofolate as well as synthesize dTMP via thymidylate synthase. (11) Eventually, 
these enzymes also assist in pyrimidine production in the parasite. The pyrimethamine 
component of SP is an antifolate that inhibits dihydrofolate reductase, therefore, 
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preventing pyrimidine synthesis in the parasite. Several point mutations in PfDHFR at 
N511, C59N, and I164L confer pyrimethamine resistance by reducing the binding 
affinity of the enzyme for its substrate (7, 11). Combinations of these mutations result in 
varying levels of resistance. 
 
Artemisinin Combined Therapy (ACT) 
The rapid spread in SP-resistant P. falciparum necessitated the development and 
implementation of yet another weapon in the fight against malaria. As resistance to CQ 
monotherapy and SP emerged, artemisinin-based combination therapies (ACTs) have 
become the gold standard treatment for malaria. Artemisinin is derived from the dried 
leaves of the sweet woodworm herb. The active ingredient, qinghaosu, was isolated in 
the 1970s and has been an effective agent against many organisms in the genus 
Plasmodium (1, 12). This combination therapy consists of 1 rapid-acting parent drug 
paired with 1 longer-acting partner drug of a different class. Parent drugs tend to be 
derivatives of artemisinin, including dihydroartemisinin, artesunate and artemether, 
while partner drugs are often derivatives of several drugs. Lumefantrine, mefloquine, 
and amodiaquine are among the most common partner drugs used in ACTs (1, 5).The 
parent drug acts on the parasite in the gametocyte stage to reduce parasitemia quickly 
within the first 1-4 days. Activation of the slower acting partner drug follows and is 
responsible for clearing the remaining parasites (5, 11). It is also recognized that more 
data is needed to determine plasma conversion rates of each drug in the combination 
therapies (13). 
 
Artemisinins act on P. falciparum in a variety of ways. One of the most notable is by 
inhibiting the phosphatidylinositol-3-kinase (PfPI3K), which is an enzyme that assists in 
endocytosis and transportation of host hemoglobin within the cytoplasm of the parasitic 
organism (14). PfPI3K inhibition results in loss of hemoglobin transport to the parasitic 
digestive vacuole for degradation, therefore, preventing free amino acid accumulation 
for further parasitic growth.  
 
Emerging Resistance to ACTs 
The first region of the world to receive ACTs, southeast Asia, was one that experienced 
low levels of malaria transmission and exposure to new infection after completion of 
therapy was unlikely. Infections in these areas were very susceptible to ACTs and often 
cleared completely (1). Contrastingly, ACTs administered in high transmission areas, 
including sub-Saharan Africa, saw a dramatic decrease in efficacy. These results can 
be attributed to the fact that people in this region are often exposed to new infections 
during the window of time when the amount of partner drug in the body is decreasing (1, 
13). It is in this critical time period where ACT resistance has begun to emerge. A 2006 
study carried out in Africa indicated that exposure to new infections during this time 
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period resulted in selection of parasites that were resistant to the long-acting partner 
drug as there was selection pressure for remaining parasites able to evade the partner 
drug (1). Administration of sub therapeutic drug levels reports inaccurate drug efficacy 
and allows resistance to occur at a rapid rate. 
 
Artemisinin resistance can be classified as a delayed clearance phenotype (DCP), 
meaning the time taken for the elimination of malaria parasites is prolonged. Studies 
have identified that the resistance mechanisms developed in the parasite are specific to 
the ring stage of the malaria parasite life cycle (13). Artemisinin is activated by the 
binding of FPIX heme, a byproduct of Hb metabolism to its endoperoxide moiety. As low 
levels of FPIX heme exist in the environment prior to hemoglobin digestion, artemisinin 
resistance is incurred early in parasitic development, in the ring stage (13, 15). As 
metabolism continues, the levels of FPIX heme increases and ultimately activates 
artemisinin for therapeutic use.  
 
Currently, the exact mechanism of DCP is unknown, but a genetic marker in P. 
falciparum for artemisinin resistance has been identified; a mutation with C580Y in 
PfKelch13 (1, 5, 13). PfKelch13 is a protein adaptor to E3 ubiquitin ligase. Kelch family 
proteins have been found in other species and have been associated with organization 
and protein interaction. Additional studies must be completed to fully understand 
kelch13 functions (11). Artemisinin-resistant strains of P. falciparum show the C580Y 
mutation paired with elevated levels of phosphatidylinositol-3 kinase (PfPI3K). This 
enzyme produces phosphatidylinositol-3-phosphate (PI3P), which is a lipid involved in 
cellular exocytosis. Upon polyubiquitination of PfPI3K and subsequent binding to 
PfKech13 protein, proteolysis of PfPI3K would normally occur. However, with a PfKelch 
13 mutation, polyubiquitination of PfPI3K and binding to PfKelch13 occurred less 
frequently leading to an increase in kinase levels and PI3P (14). Additional studies 
showed that in an absence of PfKelch13 mutations, elevated PI3P also induced 
artemisinin resistance but was responsive to regulation by PfKelch13. As a result, the 
lipid PI3P product is thought to be the key factor of artemisinin resistance, while PfPI3K 
must be a target enzyme for malaria treatments going forward. 
 
This is important in the identification of artemisinin-resistant strains as well as for 
tracking the spread of the mutant parasite. ACTs continue to remain the top choice for 
treatment of malaria, however, one of its greatest strengths may lead to its demise. The 
common component in all combinations of ACTs is artemisinin, so the spread of 
artemisinin-resistance throughout the parasite life cycle stages threatens worldwide 
treatment success. 
 
Current Preventative Intervention 
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In addition to researching mechanisms of drug resistance after parasitic infection, 
scientists have also begun to delve into the area of prevention in the form of vaccines. 
Although scientists have elucidated several targeted mechanisms of drug resistance, 
there are still many gaps in our armament against malaria. GlaxoSmithKline (GSK) has 
manufactured the only known first-generation vaccine for malaria, which has recently 
finished phase III clinical trial, the largest known malaria vaccine clinical trial in Africa. 
This vaccine, RTS,S/ASO1, is intended to provide partial protection rather than 
complete protection against malaria in children 6 weeks of age and older . In other 
words, vaccinated children may still contract malaria if transmission is high enough.  
 
Final results of Phase 3 showed that the vaccine prevented 4 in 10 cases of malaria and 
3 in 10 cases of severe malaria in a four-year time frame among the children who 
received 4 doses of the vaccine. This shows that the vaccine impacts incidence rather 
than the overall number of people developing the disease. Long-term efficacy of the 
vaccine declined over time and more studies are needed to determine steps and dosing 
to improve this efficacy. The positive results of Phase 3 prompted the WHO to endorse 
recommendations to implement the malaria vaccine implementation programme (MVIP), 
involving 3 sub-Saharan African countries. In 2019, vaccinations began in Malawi, 
Ghana, and Kenya and Phase 4 studies will be conducted in these pilot areas for 
effectiveness and potential side effects. The program is expected to last through 2023 
and will be a major determinant in the WHO’s decision of whether or not to employ the 
vaccine on a more wide-spread scale. 
 
The basis of the immunological mechanisms of the vaccine is summarized here. The 
stage of P. falciparum inoculated into the human bloodstream is the sporozoite. A 
protein called circumsporozoite protein (CS) covers the sporozoite surface and 
modulates entry into hepatocytes. The protein consists of central NANP repeats and 
flanking regions of non-repeats. The vaccine includes RTS,S which is a chimeric protein 
composed of CS NANP repeats fused to the hepatitis B virus surface antigen and AS01 
adjuvant composed primarily of lipids that enhance immune response. Administration of 
the vaccine increases serum levels of anti-NANP IgG antibodies and ultimately reduces 
the rate of hepatocyte invasion and development of new blood stage infections. (18,19) 
 
Additional questions have been raised regarding the role of cell-mediated immune (CMI) 
response. The available date suggests that protection is primarily due to antibodies, but 
there is some evidence to support contribution from CD8+ T cells in killing intracellular 
hepatocyte infection (18). Any modifications to the existing vaccine should aim, at a 




The world as malaria knows it has drastically changed over the past several thousands 
of years as scientists have developed a wider and stronger array of defenses. 
Researchers have elucidated malarial parasite life cycles and mechanisms of attack 
and paved the way for use of targeted drug therapies. Despite these efforts, the P. 
falciparum parasite continues to display its strength and resistance to pharmacological 
intervention. The major mutations in the P. falciparum genome conferring antimalarial 
resistance such as PfCRT,  PfDHPS, and PfKelch13 have raised the stakes once again. 
Researchers retaliate with the release of new combination therapies and identification of 
molecular markers of drug resistance. The molecular markers are helpful in locating 
emergence from various foci and can then be monitored to ensure administration of 
appropriate treatments for a given region of the world.  
 
Concern regarding drug resistance remains the location to which the resistance 
reaches. Emergence of chloroquine and ACT-resistant strains pose exceptional threat 
to inhabitants of malaria endemic areas in Africa. These regions lack resources for and 
accessibility to newly developed drugs for malaria treatment. Antimalarial drug 
resistance remains one of the greatest challenges in the prevention and control of 
malaria. Although studies of parasitic and drug mechanisms have significantly propelled 
our current knowledge in targeted treatment methods, additional focus on vector control 
and vaccine development is essential in eradicating malaria. Improper control of vectors 
and inadequate vaccination could lead to neutralization of progress achieved thus far in 
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